Analyst Highlights Growth Catalysts for Merck (MRK) Stock

We recently published Wall Street Analysts Like These 10 Stocks. Merck & Co., Inc. (NYSE:MRK) is one of the stocks analysts were recently talking about.

Bill Nygren, Oakmark Funds partner and CIO, recently said during a program on CNBC that he likes Merck & Co., Inc. (NYSE:MRK). Here is how the analyst made the bull case for the stock:

“Merck has some other really interesting assets including strong franchises in vaccines, which is another controversy area today. But we think that will continue to be a good profit source for them. They have a good business in animal health, and then in the pipeline they have a lot of experiments of combining KEYTRUDA with other drugs to more target specific cancers, and we think there’s a reasonable chance that at least one of those will be successful.”

Impax US Sustainable Economy Fund stated the following regarding Merck & Co., Inc. (NYSE:MRK) in its second quarter 2025 investor letter:

“Merck & Co., Inc. (NYSE:MRK) (Health Care, Pharmaceuticals) has a high Corporate Resilience score, and is contributing to a more robust and sustainable health care system through its leading drug and vaccine discovery. The stock’s weakness in Q2 was driven by a combination of concerns about its drug pipeline, particularly the competition from generic versions of Keytruda, and weaker market sentiment around Health Care stocks.”

While we acknowledge the potential of MRK as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.